China’s Jemincare nabs $650M biobucks pact with Roche’s Genentech for prostate cancer hopeful

After penning a deal with Orion back in May, Jemincare is back at the licensing deal table, inking a development and sales deal with Roche’s Genentech unit that is on the lookout for a new prostate cancer drug after the recent flop of its phase 3 asset ipatasertib.

The pact, worth $60 million with an additional $590 million in biobucks also thrown into the mix, sees Genentech buy Jemincare’s androgen receptor degrader JMKX002992. read more